FDA Approves Lilly's Kisunla To Treat Early Symptomatic Alzheimer's Disease
3/7 03:01
(RTTNews) - The U.S. Food and Drug Administration approved Eli Lilly and Co.'s (LLY) Kisunla (donanemab-azbt, 350 mg/20 mL once-monthly injection for IV infusion), the company's Alzheimer's treatment for adults with early symptomatic Alzheimer's disease, which includes people wit...